Biocon informs about media release
Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Pharma Limited Receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
